Download PDF
Thromb Haemost 2020; 120(04): 565-578
DOI: 10.1055/s-0040-1702920
T&H Historical Series
Georg Thieme Verlag KG Stuttgart · New York

Platelet Inhibition in Acute Coronary Syndrome and Percutaneous Coronary Intervention: Insights from the Past and Present

Diana A. Gorog
1   National Heart and Lung Institute, Imperial College, London, United Kingdom
2   Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom
,
Tobias Geisler
3   Department of Cardiology and Angiology, University Hospital, Eberhard-Karls-University Tuebingen, Tuebingen, Germany
› Author Affiliations
Further Information

Publication History

07 September 2019

09 January 2020

Publication Date:
19 February 2020 (online)

   Permissions and Reprints

Abstract

Platelet activation and aggregation have a pivotal role in arterial thrombosis and in the pathogenesis of both acute coronary syndromes (ACS) and in the thrombotic complications that occur in patients undergoing percutaneous coronary intervention (PCI). The past 30 years has seen the progress from early trials of clopidogrel and glycoprotein IIb/IIIa inhibitors to the application of more potent P2Y12 inhibitors prasugrel and ticagrelor. Early enthusiasm for newer and more potent antiplatelet agents, which could reduce ischemic events, has led to the understanding of the importance of bleeding and a desire to individualize and optimize treatment. It has increasingly become apparent that the potency and duration of dual antiplatelet therapy (DAPT) has to reflect the balance between ischemic and bleeding risk. Recently, multiple strategies have been proposed to individualize DAPT intensity and duration to reduce the bleeding and ischemic risks. Strategies of de-escalation of DAPT intensity, as well as shorter (less than a year) or more prolonged (beyond a year) treatment have been proposed, as well as platelet function test and genotype guidance of P2Y12 inhibitor therapy. Herein, we provide an overview of the progress in the field of antiplatelet therapy for ACS and PCI over the years, showing the current directions of travel. Ongoing studies focusing on personalized antiplatelet treatment will hopefully yield further insight into ways of optimizing outcomes for the individual.

Keywords

Acute Myocardial Infarction - antiplatelet agents - arterial thrombosis - thrombosis - coagulation inhibitors
 

  • References

  • 1 Davies MJ. The birth, growth and consequences of the atherosclerotic plaque. Dialogues Cardiovasc Med 1999; 4: 115-178
    PubMedGoogle Scholar
  • 2 Davies MJ. The pathophysiology of acute coronary syndromes. Heart 2000; 83 (03) 361-366
    CrossrefPubMedGoogle Scholar
  • 3 Moscucci M, Fox KAA, Cannon CP. , et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24 (20) 1815-1823
    CrossrefPubMedGoogle Scholar
  • 4 Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG. ; Canadian Acute Coronary Syndromes Registries Investigators. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005; 150 (04) 690-694
    CrossrefPubMedGoogle Scholar
  • 5 Yeh RW, Secemsky EA, Kereiakes DJ. , et al; DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016; 315 (16) 1735-1749
    CrossrefPubMedGoogle Scholar
  • 6 Costa F, van Klaveren D, James S. , et al; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389 (10073): 1025-1034
    CrossrefPubMedGoogle Scholar
  • 7 Abu-Assi E, Raposeiras-Roubin S, Cobas-Paz R. , et al. Assessing the performance of the PRECISE-DAPT and PARIS risk scores for predicting one-year out-of-hospital bleeding in acute coronary syndrome patients. EuroIntervention 2018; 13 (16) 1914-1922
    CrossrefPubMedGoogle Scholar
  • 8 Urban P, Mehran R, Colleran R. , et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 2019; 140 (03) 240-261
    CrossrefPubMedGoogle Scholar
  • 9 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2 (8607): 349-360
    PubMedGoogle Scholar
  • 10 Collaboration A. ; Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86
    CrossrefPubMedGoogle Scholar
  • 11 Ibanez B, James S, Agewall S. , et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 12 Roffi M, Patrono C, Collet J-PP. , et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
    CrossrefPubMedGoogle Scholar
  • 13 Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. ; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 (07) 494-502
    CrossrefPubMedGoogle Scholar
  • 14 Leon MB, Baim DS, Popma JJ. , et al; Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998; 339 (23) 1665-1671
    CrossrefPubMedGoogle Scholar
  • 15 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
    CrossrefPubMedGoogle Scholar
  • 16 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedGoogle Scholar
  • 17 Sibbing D, Angiolillo DJ, Huber K. Antithrombotic therapy for acute coronary syndrome: past, present and future. Thromb Haemost 2017; 117 (07) 1240-1248
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Velders MA, Abtan J, Angiolillo DJ. , et al; PLATO Investigators. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 2016; 102 (08) 617-625
    CrossrefPubMedGoogle Scholar
  • 19 Schüpke S, Neumann F-JJ, Menichelli M. , et al; ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019; 381 (16) 1524-1534
    CrossrefPubMedGoogle Scholar
  • 20 Hamm CW, Heeschen C, Goldmann B. , et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab antiplatelet therapy in unstable refractory angina (CAPTURE) study investigators. N Engl J Med 1999; 340 (21) 1623-1629
    CrossrefPubMedGoogle Scholar
  • 21 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338 (21) 1488-1497
    CrossrefPubMedGoogle Scholar
  • 22 Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339 (07) 436-443
    CrossrefPubMedGoogle Scholar
  • 23 D'Ascenzo F, Bollati M, Clementi F. , et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2013; 167 (02) 575-584
    CrossrefPubMedGoogle Scholar
  • 24 Stone GW, Witzenbichler B, Guagliumi G. , et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358 (21) 2218-2230
    CrossrefPubMedGoogle Scholar
  • 25 Dangas G, Aymong ED, Mehran R. , et al; CADILLAC Investigators. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). Am J Cardiol 2004; 94 (08) 983-988
    CrossrefPubMedGoogle Scholar
  • 26 Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009; 6 (04) 273-282
    PubMedGoogle Scholar
  • 27 Gorog DA, Sweeny JM, Fuster V. Antiplatelet drug ‘resistance’. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?. Nat Rev Cardiol 2009; 6 (05) 365-373
    PubMedGoogle Scholar
  • 28 Hochholzer W, Trenk D, Bestehorn H-PP. , et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48 (09) 1742-1750
    CrossrefPubMedGoogle Scholar
  • 29 Geisler T, Zürn C, Simonenko R. , et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31 (01) 59-66
    CrossrefPubMedGoogle Scholar
  • 30 Morel O, El Ghannudi S, Jesel L. , et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol 2011; 57 (04) 399-408
    CrossrefPubMedGoogle Scholar
  • 31 Cuisset T, Frere C, Quilici J. , et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009; 123 (04) 597-603
    CrossrefPubMedGoogle Scholar
  • 32 Frere C, Cuisset T, Quilici J. , et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98 (04) 838-843
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Alexopoulos D, Xenogiannis I, Vlachakis P, Tantry U, Gurbel PA. Peri-procedural platelet reactivity in percutaneous coronary intervention. Thromb Haemost 2018; 118 (07) 1131-1140
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 de Carvalho LP, Fong A, Troughton R. , et al. Prognostic implications of dual platelet reactivity testing in acute coronary syndrome. Thromb Haemost 2018; 118 (02) 415-426
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Winter M-PP, Grove EL, De Caterina R. , et al. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Eur Heart J Cardiovasc Pharmacother 2017; 3 (04) 221-234
    CrossrefPubMedGoogle Scholar
  • 36 Shuldiner AR, O'Connell JR, Bliden KP. , et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302 (08) 849-857
    CrossrefPubMedGoogle Scholar
  • 37 Mega JL, Close SL, Wiviott SD. , et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360 (04) 354-362
    CrossrefPubMedGoogle Scholar
  • 38 Simon T, Verstuyft C, Mary-Krause M. , et al; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360 (04) 363-375
    CrossrefPubMedGoogle Scholar
  • 39 Mega JL, Simon T, Collet J-PP. , et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304 (16) 1821-1830
    CrossrefPubMedGoogle Scholar
  • 40 Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306 (24) 2704-2714
    CrossrefPubMedGoogle Scholar
  • 41 Sorich M, Rowlan A, McKinnon R. , et al. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following PCI and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 2014; 7: 895-902
    PubMedGoogle Scholar
  • 42 Frére C, Cuisset T, Gaborit B, Alessi MC, Hulot JS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J Thromb Haemost 2009; 7 (08) 1409-1411
    CrossrefPubMedGoogle Scholar
  • 43 Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 8 (08) 1678-1684
    CrossrefPubMedGoogle Scholar
  • 44 Wallentin L, James S, Storey RF. , et al; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376 (9749): 1320-1328
    CrossrefPubMedGoogle Scholar
  • 45 Claassens DMF, Vos GJA, Bergmeijer TO. , et al. A genotype-guided strategy for Oral P2Y12 inhibitors in primary PCI. N Engl J Med 2019; 381 (17) 1621-1631
    CrossrefPubMedGoogle Scholar
  • 46 Price MJ, Berger PB, Teirstein PS. , et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305 (11) 1097-1105
    CrossrefPubMedGoogle Scholar
  • 47 Trenk D, Stone GW, Gawaz M. , et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59 (24) 2159-2164
    CrossrefPubMedGoogle Scholar
  • 48 Collet J-PP, Cuisset T, Rangé G. , et al; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367 (22) 2100-2109
    CrossrefPubMedGoogle Scholar
  • 49 Cayla G, Cuisset T, Silvain J. , et al; ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 2016; 388 (10055): 2015-2022
    CrossrefPubMedGoogle Scholar
  • 50 Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. J Am Coll Cardiol 2013; 61 (21) 2115-2129
    CrossrefPubMedGoogle Scholar
  • 51 Flierl U, Zauner F, Sieweke J-TT. , et al. Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction. Thromb Haemost 2017; 117 (01) 99-104
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Bhatt DL, Stone GW, Mahaffey KW. , et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368 (14) 1303-1313
    CrossrefPubMedGoogle Scholar
  • 53 Droppa M, Vaduganathan M, Venkateswaran RV. , et al. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: a global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation 2019; 137: 205-212
    CrossrefPubMedGoogle Scholar
  • 54 Silvain J, Storey RF, Cayla G. , et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116 (02) 369-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Bellandi B, Zocchi C, Xanthopoulou I. , et al. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol 2016; 221: 567-571
    CrossrefPubMedGoogle Scholar
  • 56 Kubica J, Adamski P, Ostrowska M. , et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37 (03) 245-252
    CrossrefPubMedGoogle Scholar
  • 57 Duerschmied D, Bode C. Life-saving therapy versus symptom relief: anti-platelet agents and opioids in coronary intervention. Thromb Haemost 2018; 118 (08) 1350-1351
    Article in Thieme ConnectPubMedGoogle Scholar
  • 58 Ibrahim K, Shah R, Goli RR. , et al. Fentanyl delays the platelet inhibition effects of oral ticagrelor: full report of the PACIFY randomized clinical trial. Thromb Haemost 2018; 118 (08) 1409-1418
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Parodi G, Valenti R, Bellandi B. , et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 2013; 61 (15) 1601-1606
    CrossrefPubMedGoogle Scholar
  • 60 Parodi G, Bellandi B, Xanthopoulou I. , et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014; 8 (01) e001593
    PubMedGoogle Scholar
  • 61 Nimmo WS, Heading RC, Wilson J, Tothill P, Prescott LF. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol 1975; 2 (06) 509-513
    CrossrefPubMedGoogle Scholar
  • 62 Thomas MR, Morton AC, Hossain R. , et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost 2016; 116 (01) 96-102
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 McCarthy CP, Bhambhani V, Pomerantsev E, Wasfy JH. In-hospital outcomes in invasively managed acute myocardial infarction patients who receive morphine. J Interv Cardiol 2018; 31 (02) 150-158
    CrossrefPubMedGoogle Scholar
  • 64 Puymirat E, Lamhaut L, Bonnet N. , et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J 2016; 37 (13) 1063-1071
    CrossrefPubMedGoogle Scholar
  • 65 Farag M, Spinthakis N, Srinivasan M, Sullivan K, Wellsted D, Gorog DA. Morphine analgesia pre-PPCI is associated with prothrombotic state, reduced spontaneous reperfusion and greater infarct size. Thromb Haemost 2018; 118 (03) 601-612
    Article in Thieme ConnectPubMedGoogle Scholar
  • 66 de Waha S, Eitel I, Desch S. , et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol 2015; 104 (09) 727-734
    CrossrefPubMedGoogle Scholar
  • 67 Bonin M, Mewton N, Roubille F. , et al; CIRCUS Study Investigators. Effect and safety of morphine use in acute anterior ST-segment elevation myocardial infarction. J Am Heart Assoc 2018; 7 (04) e006833
    PubMedGoogle Scholar
  • 68 Lapostolle F, Van't Hof AW, Hamm CW. , et al; ATLANTIC Investigators. Morphine and ticagrelor interaction in primary percutaneous coronary intervention in st-segment elevation myocardial infarction: ATLANTIC-morphine. Am J Cardiovasc Drugs 2019; 19 (02) 173-183
    CrossrefPubMedGoogle Scholar
  • 69 Spinthakis N, Gue Y, Farag M. , et al. Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. Europace 2019; 21 (09) 1297-1306
    CrossrefPubMedGoogle Scholar
  • 70 Sikora J, Niezgoda P, Barańska M. , et al. METoclopramide administration as a strategy to overcome morphine-ticagrelor interaction in patients with unstable Angina pectorIS-the METAMORPHOSIS trial. Thromb Haemost 2018; 118 (12) 2126-2133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 71 Rollini F, Franchi F, Hu J. , et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol 2016; 67 (17) 1994-2004
    PubMedGoogle Scholar
  • 72 Parodi G, Xanthopoulou I, Bellandi B. , et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol 2015; 65 (05) 511-512
    CrossrefPubMedGoogle Scholar
  • 73 Asher E, Frydman S, Katz M. , et al; For The PLATIS (Platelets and Thrombosis in Sheba) Study Group. Chewing versus swallowing ticagrelor to accelerate platelet inhibition in acute coronary syndrome - the CHEERS study. Thromb Haemost 2017; 117 (04) 727-733
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Giannopoulos G, Deftereos S, Kolokathis F, Xanthopoulou I, Lekakis J, Alexopoulos D. P2Y12 receptor antagonists and morphine: a dangerous liaison?. Circ Cardiovasc Interv 2016; 9 (09) e004229
    PubMedGoogle Scholar
  • 75 Kubica J, Kubica A, Jilma B. , et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. Int J Cardiol 2016; 215: 201-208
    CrossrefPubMedGoogle Scholar
  • 76 Bonaca MP, Bhatt DL, Cohen M. , et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372 (19) 1791-1800
    CrossrefPubMedGoogle Scholar
  • 77 Vranckx P, Valgimigli M, Jüni P. , et al; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 2018; 392 (10151): 940-949
    CrossrefPubMedGoogle Scholar
  • 78 Feres F, Costa RA, Abizaid A. , et al; OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013; 310 (23) 2510-2522
    PubMedGoogle Scholar
  • 79 Kim B-KK, Hong M-KK, Shin D-HH. , et al; RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012; 60 (15) 1340-1348
    CrossrefPubMedGoogle Scholar
  • 80 Urban P, Meredith IT, Abizaid A. , et al; LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med 2015; 373 (21) 2038-2047
    CrossrefPubMedGoogle Scholar
  • 81 Varenne O, Cook S, Sideris G. , et al; SENIOR investigators. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 2018; 391 (10115): 41-50
    CrossrefPubMedGoogle Scholar
  • 82 Yin S-H-LH, Xu P, Wang B. , et al. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ 2019; 365: l2222
    CrossrefPubMedGoogle Scholar
  • 83 Cuisset T, Deharo P, Quilici J. , et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017; 38 (41) 3070-3078
    CrossrefPubMedGoogle Scholar
  • 84 Sibbing D, Aradi D, Jacobshagen C. , et al; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 2017; 390 (10104): 1747-1757
    CrossrefPubMedGoogle Scholar
  • 85 Hein R, Gross L, Aradi D. , et al; Collaborators. Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. EuroIntervention 2019; 15 (06) e513-e521
    CrossrefPubMedGoogle Scholar
  • 86 Gross L, Trenk D, Jacobshagen C. , et al. Genotype-phenotype association and impact on outcomes following guided De-escalation of anti-platelet treatment in acute coronary syndrome patients: the TROPICAL-ACS genotyping substudy. Thromb Haemost 2018; 118 (09) 1656-1667
    Article in Thieme ConnectPubMedGoogle Scholar
  • 87 Watanabe H, Domei T, Morimoto T. , et al; STOPDAPT-2 Investigators. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019; 321 (24) 2414-2427
    CrossrefPubMedGoogle Scholar
  • 88 Hahn J-YY, Song YB, Oh J-HH. , et al; SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 2019; 321 (24) 2428-2437
    CrossrefPubMedGoogle Scholar
  • 89 Hahn J-Y, Song YB, Oh J-H. , et al; SMART-DATE investigators. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 2018; 391 (10127): 1274-1284
    CrossrefPubMedGoogle Scholar
  • 90 Gimbel ME. Randomised comparison of clopidogrel versus ticagrelor or prasugrel in patients of 70 years or older with non-ST-elevation acute coronary syndrome - POPular AGE. European Society of Cardiology 2019. Available at: https://www.acc.org/latest-in-cardiology/clinical-trials/2019/08/30/09/59/popular-age . Accessed Februray 3, 2020
    PubMedGoogle Scholar
  • 91 Mehran R, Baber U, Sharma SK. , et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019; 381 (21) 2032-2042
    CrossrefPubMedGoogle Scholar
  • 92 Delesque-Touchard N, Pflieger AM, Bonnet-Lignon S. , et al. SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?. Thromb Res 2014; 134 (03) 693-703
    CrossrefPubMedGoogle Scholar
  • 93 Storey RF, Gurbel PA, ten Berg J. , et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J 2019 Doi: 10.1093/eurheartj/ehz807
    PubMedGoogle Scholar
  • 94 Wong P, Crain E, Watson C. , et al. Differential effects of P2Y1 versus P2Y12 receptor antagonism on thrombosis and bleeding in rabbits. Eur Heart J 2013; 34: 1431-P1431
    CrossrefPubMedGoogle Scholar
  • 95 Gremmel T, Yanachkov IB, Yanachkova MI. , et al. Synergistic inhibition of both P2Y1 and P2Y12 adenosine diphosphate receptors as novel approach to Rapidly attenuate platelet-mediated thrombosis. Arterioscler Thromb Vasc Biol 2016; 36 (03) 501-509
    CrossrefPubMedGoogle Scholar
  • 96 Li J, Vootukuri S, Shang Y. , et al. RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2014; 34 (10) 2321-2329
    CrossrefPubMedGoogle Scholar
  • 97 Schwarz M, Meade G, Stoll P. , et al. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006; 99 (01) 25-33
    CrossrefPubMedGoogle Scholar
  • 98 McFadyen JD, Schaff M, Peter K. Current and future antiplatelet therapies: emphasis on preserving haemostasis. Nat Rev Cardiol 2018; 15 (03) 181-191
    CrossrefPubMedGoogle Scholar
  • 99 Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke 2011; 42 (08) 2149-2153
    CrossrefPubMedGoogle Scholar
  • 100 Bartunek J, Barbato E, Heyndrickx G, Vanderheyden M, Wijns W, Holz JB. Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor. J Cardiovasc Transl Res 2013; 6 (03) 355-363
    CrossrefPubMedGoogle Scholar
  • 101 Lei X, Reheman A, Hou Y. , et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014; 111 (02) 279-289
    Article in Thieme ConnectPubMedGoogle Scholar
  • 102 Nylander S, Wågberg F, Andersson M, Skärby T, Gustafsson D. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man. J Thromb Haemost 2015; 13 (08) 1494-1502
    CrossrefPubMedGoogle Scholar
  • 103 Morrow DA, Braunwald E, Bonaca MP. , et al; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15) 1404-1413
    CrossrefPubMedGoogle Scholar
  • 104 Aisiku O, Peters CG, De Ceunynck K. , et al. Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar. Blood 2015; 125 (12) 1976-1985
    CrossrefPubMedGoogle Scholar
  • 105 Wong PC, Seiffert D, Bird JE. , et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017; 9 (371) eaaf5294
    CrossrefPubMedGoogle Scholar
  • 106 Wilson SJ, Ismat FA, Wang Z. , et al. PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol 2018; 38 (02) 448-456
    CrossrefPubMedGoogle Scholar
  • 107 Ohlmann P, Hechler B, Ravanat C. , et al. Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost 2008; 6 (06) 1003-1011
    CrossrefPubMedGoogle Scholar
  • 108 Voors-Pette C, Lebozec K, Dogterom P. , et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol 2019; 39 (05) 956-964
    CrossrefPubMedGoogle Scholar
  • 109 Ungerer M, Rosport K, Bültmann A. , et al. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011; 123 (17) 1891-1899
    CrossrefPubMedGoogle Scholar